Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more
Adaptimmune Therapeutics Plc (ADAP) - Net Assets
Latest net assets as of June 2025: $-70.96 Million USD
Based on the latest financial reports, Adaptimmune Therapeutics Plc (ADAP) has net assets worth $-70.96 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($130.63 Million) and total liabilities ($201.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-70.96 Million |
| % of Total Assets | -54.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | -96.53% |
| 10-Year Change | -95.44% |
| Growth Volatility | 3071.27 |
Adaptimmune Therapeutics Plc - Net Assets Trend (2011–2024)
This chart illustrates how Adaptimmune Therapeutics Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Adaptimmune Therapeutics Plc (2011–2024)
The table below shows the annual net assets of Adaptimmune Therapeutics Plc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $11.85 Million | -70.01% |
| 2023-12-31 | $39.51 Million | -51.74% |
| 2022-12-31 | $81.88 Million | -60.25% |
| 2021-12-31 | $205.96 Million | -39.64% |
| 2020-12-31 | $341.23 Million | +175.99% |
| 2019-12-31 | $123.64 Million | -49.92% |
| 2018-12-31 | $246.88 Million | +21.63% |
| 2017-12-31 | $202.98 Million | +22.18% |
| 2016-12-31 | $166.14 Million | -36.00% |
| 2015-12-31 | $259.61 Million | +0.00% |
| 2014-12-31 | $259.61 Million | +10672.20% |
| 2013-12-31 | $2.41 Million | +211.80% |
| 2012-12-31 | $-2.16 Million | -1615.51% |
| 2011-12-31 | $-125.66K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adaptimmune Therapeutics Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 108432564229.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.08 Million | 17.60% |
| Other Comprehensive Income | $-1.90 Million | -16.05% |
| Other Components | $1.11 Billion | 9331.19% |
| Total Equity | $11.85 Million | 100.00% |
Adaptimmune Therapeutics Plc Competitors by Market Cap
The table below lists competitors of Adaptimmune Therapeutics Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chinese People Holdings Company Limited
F:KEH
|
$14.56 Million |
|
CORON.GL.RES. CDIS/10/1
F:0QE
|
$14.57 Million |
|
KAVDEFENCE
NSE:KAVDEFENCE
|
$14.58 Million |
|
FIRST REAL JSC
VN:FIR
|
$14.58 Million |
|
Alaska Energy Metals Corporation
OTCQB:AKEMF
|
$14.55 Million |
|
PPK Group Limited
PINK:PLPKF
|
$14.55 Million |
|
Vext Science Inc
OTCQX:VEXTF
|
$14.55 Million |
|
Eastwood Bio-Medical Canada Inc
PINK:EWOOF
|
$14.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adaptimmune Therapeutics Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 39,513,000 to 11,849,000, a change of -27,664,000 (-70.0%).
- Net loss of 70,814,000 reduced equity.
- New share issuances of 29,172,000 increased equity.
- Other comprehensive income increased equity by 1,846,000.
- Other factors increased equity by 12,132,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-70.81 Million | -597.64% |
| Share Issuances | $29.17 Million | +246.2% |
| Other Comprehensive Income | $1.85 Million | +15.58% |
| Other Changes | $12.13 Million | +102.39% |
| Total Change | $- | -70.01% |
Book Value vs Market Value Analysis
This analysis compares Adaptimmune Therapeutics Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.77x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.13 | $0.04 | x |
| 2013-12-31 | $0.05 | $0.04 | x |
| 2014-12-31 | $7.25 | $0.04 | x |
| 2015-12-31 | $7.25 | $0.04 | x |
| 2016-12-31 | $2.35 | $0.04 | x |
| 2017-12-31 | $2.31 | $0.04 | x |
| 2018-12-31 | $2.54 | $0.04 | x |
| 2019-12-31 | $1.18 | $0.04 | x |
| 2020-12-31 | $2.40 | $0.04 | x |
| 2021-12-31 | $1.32 | $0.04 | x |
| 2022-12-31 | $0.51 | $0.04 | x |
| 2023-12-31 | $0.20 | $0.04 | x |
| 2024-12-31 | $0.05 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adaptimmune Therapeutics Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -597.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -39.78%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 20.76x
- Recent ROE (-597.64%) is below the historical average (-151.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.25 Million |
| 2013 | -527.07% | -2100.85% | 0.01x | 23.04x | $-12.94 Million |
| 2014 | -8.32% | -201.36% | 0.04x | 1.16x | $-47.55 Million |
| 2015 | -8.32% | -201.36% | 0.04x | 1.16x | $-47.55 Million |
| 2016 | -43.08% | -504.15% | 0.06x | 1.41x | $-88.19 Million |
| 2017 | -34.55% | -185.39% | 0.13x | 1.39x | $-90.44 Million |
| 2018 | -38.69% | -160.51% | 0.22x | 1.12x | $-120.20 Million |
| 2019 | -110.94% | -12225.04% | 0.01x | 1.47x | $-149.53 Million |
| 2020 | -38.12% | -3286.81% | 0.01x | 1.32x | $-164.21 Million |
| 2021 | -76.76% | -2570.99% | 0.01x | 2.28x | $-178.69 Million |
| 2022 | -202.08% | -609.46% | 0.08x | 4.02x | $-173.64 Million |
| 2023 | -288.19% | -188.90% | 0.21x | 7.15x | $-117.82 Million |
| 2024 | -597.64% | -39.78% | 0.72x | 20.76x | $-72.00 Million |
Industry Comparison
This section compares Adaptimmune Therapeutics Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adaptimmune Therapeutics Plc (ADAP) | $-70.96 Million | 0.00% | N/A | $14.55 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |